FCH
IMNM icon

Freestone Capital Holdings’s Immunome IMNM Stock Holding History

Freestone Capital Holdings’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Sell
60,589
-925
-2% -$19.8K 0.03% 233
2026
Q1 		$1.35M Sell
61,514
-35
-0.1% -$779 0.04% 214
2025
Q4 		$1.32M Sell
61,549
-78
-0.1% -$1.37K 0.04% 215
2025
Q3 		$722K Buy
61,627
+28
+0% +$279 0.02% 280
2025
Q2 		$573K Sell
61,599
-82
-0.1% -$672 0.02% 276
2025
Q1 		$415K Buy
+61,681
New +$592K 0.02% 308

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Freestone Capital Holdings's IMNM Position: Q2 2026 in Review

Freestone Capital Holdings reduced its Immunome (IMNM) stake by 1.5% in Q2 2026, selling an estimated $19.8K and leaving 60,589 shares worth $1.28M. The position accounts for 0.03% of the portfolio, ranked #233.

Freestone Capital Holdings first reported a position in IMNM in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.35M in Q1 2026. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Freestone Capital Holdings held 60,589 shares of Immunome worth $1.28M as of Q2 2026.
  • Freestone Capital Holdings sold 925 Immunome shares in Q2 2026, an estimated $19.8K.
  • Immunome made up 0.03% of Freestone Capital Holdings's portfolio in Q2 2026, its #233 holding.
  • Freestone Capital Holdings first reported a position in Immunome in Q1 2025 and has held it in 6 quarters since.
  • Freestone Capital Holdings's Immunome position peaked at $1.35M in Q1 2026.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.